부갑상선 질환 시장 : 유형별, 질환 유형별, 투여 경로별, 연령층별, 성별, 최종사용자별, 유통 채널별, 지역별
Parathyroid Disorders Market, By Type, By Disorder Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Geography
상품코드
:
1747292
리서치사
:
Coherent Market Insights
발행일
:
2025년 05월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
부갑상선 질환 세계 시장은 2025년에 111억 달러, 2032년에는 139억 3,000만 달러에 이르고, 2025-2032년 연평균 복합 성장률(CAGR)은 3.3%를 보일 것으로 예측됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2024 |
2025년 시장 규모 |
111억 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
3.30% |
2032년 가치 예측 |
139억 3,000만 달러 |
세계 부갑상선 질환 시장은 부갑상선 질환의 유병률 증가, 진단 기술의 발전, 새로운 치료 옵션의 개발 등을 배경으로 최근 괄목할 만한 성장세를 보이고 있습니다. 부갑상선 질환에는 부갑상선 기능 항진증과 부갑상선 기능 저하증이 포함되며, 부갑상선의 기능 이상으로 인해 체내 칼슘과 인산의 균형이 깨지는 것이 특징입니다. 이러한 질환은 뼈 건강, 심혈관계 기능, 삶의 질 전반에 심각한 영향을 미칠 수 있습니다. 부갑상선 질환에 대한 인식이 높아지고 첨단 치료법이 개발됨에 따라 세계 부갑상선 질환 시장은 예측 기간 동안 상당한 성장을 이룰 것으로 예측됩니다.
시장 역학:
세계 부갑상선 질환 시장은 부갑상선 질환, 특히 폐경 후 여성에서 원발성 부갑상선 기능 항진증의 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 또한, 부갑상선 질환에 취약한 노년층 인구 증가는 시장 성장에 박차를 가할 것으로 예측됩니다. 개선된 영상 진단 양식 및 유전자 검사와 같은 진단 기술의 발전은 부갑상선 질환의 조기 발견과 정확한 진단을 가능하게 하여 시장 성장을 더욱 촉진하고 있습니다. 또한, 표적 치료 및 최소 침습 수술과 같은 새로운 치료법의 개발로 치료 옵션이 확대되고 환자 예후가 개선되고 있습니다. 그러나 높은 치료 비용, 특정 지역에서의 부갑상선 질환에 대한 인식 부족, 일부 치료법에 따른 잠재적 부작용 등의 요인으로 인해 시장 성장이 제한될 수 있습니다. 이러한 억제요인에도 불구하고, 연구개발 활동에 대한 관심 증가, 업계와 학계와의 협력 관계, 부갑상선 질환 분야에서의 개인 맞춤형 의료 접근법의 출현 등으로 인해 시장에는 큰 성장 기회가 있습니다.
본 조사의 주요 특징
- 세계의 부갑상선 질환 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 정리하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 부갑상선 질환 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 부갑상선 질환 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 부갑상선 질환 시장, 유형별, 2020년-2032년
- 약물 클래스
- 부갑상선 호르몬(PTH) 유사체
- 비스포스포네이트
- 칼슘 자극제
- 비타민 D 유사체
- 인산 결합제
- 진단 방법
- 혈액검사
- 영상 기술
- 요검사
제5장 세계의 부갑상선 질환 시장, 질환 유형별, 2020년-2032년
- 원발성 부갑상선 기능 항진증
- 2차성 부갑상선 기능 항진증
- 3차성부갑상선 기능 항진증
- 부갑상선 기능 저하증
제6장 세계의 부갑상선 질환 시장, 투여 경로별, 2020년-2032년
제7장 세계의 부갑상선 질환 시장, 연령 그룹별, 2020년-2032년
제8장 세계의 부갑상선 질환 시장, 성별, 2020년-2032년
제9장 세계의 부갑상선 질환 시장, 최종사용자별, 2020년-2032년
- 병원
- 전문 클리닉
- 외래센터
- 연구기관
- 진단센터
- 재택 헬스케어
제10장 세계의 부갑상선 질환 시장, 유통 채널별, 2020년-2032년
제11장 세계의 부갑상선 질환 시장, 지역별, 2020년-2032년
- 북미
- 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- 아프리카
제12장 경쟁 구도
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Regeneron Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sandoz(a Novartis division)
- Otsuka Pharmaceutical Co., Ltd.
제13장 애널리스트 추천 사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고 문헌과 조사 방법
LSH
영문 목차
Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 11.10 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
3.30% |
2032 Value Projection: |
USD 13.93 Bn |
The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.
Market Dynamics:
The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.
Key Features of the Study:
- This report provides in-depth analysis of the global parathyroid disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global parathyroid disorders market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Drug Class
- Parathyroid Hormone (PTH) Analogues
- Bisphosphonates
- Calcimimetics
- Vitamin D Analogues
- Phosphate Binders
- Diagnostic Method
- Blood Tests
- Imaging Techniques
- Urine Tests
- Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
- Tertiary Hyperparathyroidism
- Hypoparathyroidism
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Outpatient Centers
- Research Institutes
- Diagnostic Centers
- Home Healthcare
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Regeneron Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sandoz (a Novartis division)
- Otsuka Pharmaceutical Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Parathyroid Disorders Market, By Type
- Global Parathyroid Disorders Market, By Disorder Type
- Global Parathyroid Disorders Market, By Route of Administration
- Global Parathyroid Disorders Market, By Age Group
- Global Parathyroid Disorders Market, By Gender
- Global Parathyroid Disorders Market, By End User
- Global Parathyroid Disorders Market, By Distribution Channel
- Global Parathyroid Disorders Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Parathyroid Disorders Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Drug Class
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parathyroid Hormone (PTH) Analogues
- Bisphosphonates
- Calcimimetics
- Vitamin D Analogues
- Phosphate Binders
- Diagnostic Method
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Blood Tests
- Imaging Techniques
- Urine Tests
5. Global Parathyroid Disorders Market, By Disorder Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Primary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Secondary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Tertiary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hypoparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Parathyroid Disorders Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Parathyroid Disorders Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Parathyroid Disorders Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Parathyroid Disorders Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Outpatient Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Healthcare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Parathyroid Disorders Market, By Distribution Channel, 202-02032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Parathyroid Disorders Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
관련자료
